GLP-1 Market
LLY $1184.78 ▲ +0.1% NVO $38.71 ▼ -0.2% PFE $28.72 ▲ +0.2% VKTX $33.03 ▼ -7.1% KLRA $11.12 ▼ -0.9% GPCR $35.06 ▼ -2.4% RHHBY $53.34 ▼ -2.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

AR882

AR882

Company
Arthrosi Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 29, 2026

Trial details
  • Completed NCT NCT04155918

    Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients

    Not yet reported Arthrosi Therapeutics 30 participants Est. completion 2020-09-03 1 site Stand-alone
    Other conditions: Gout Patients
    View official trial listing →
  • Completed NCT NCT04314986

    Multiple Ascending Dose Study of AR882 in Healthy Adult Male Volunteers

    Not yet reported Arthrosi Therapeutics 30 participants Est. completion 2019-09-18 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04347005

    The Study is Designed to Evaluate Single Ascending Doses of AR882 in Healthy Adult Males

    Not yet reported Arthrosi Therapeutics 64 participants Est. completion 2019-07-31 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04508426

    Single-dose AME Study With [14C]AR882 in Healthy Male Subjects

    Not yet reported Arthrosi Therapeutics 6 participants Est. completion 2020-08-12 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT04646889

    Pharmacokinetic Study of AR882 in Subjects With Various Degrees of Renal Impairment

    Not yet reported Arthrosi Therapeutics 46 participants Est. completion 2022-06-27 4 sites Stand-alone
    Other conditions: Renal Impairment
    View official trial listing →
  • Completed NCT NCT05119686

    Phase 2b Evaluation of Efficacy and Safety of AR882 in Gout Patients

    Not yet reported Arthrosi Therapeutics 140 participants Est. completion 2022-11-17 23 sites Stand-alone
    Other conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
    View official trial listing →
  • Completed NCT NCT05253833

    Phase 2 to Assess Efficacy and Safety in AR882 Alone or in Combination With Allopurinol in Patients With Tophaceous Gout

    Not yet reported Arthrosi Therapeutics 42 participants Est. completion 2024-10-28 12 sites Stand-alone
    Other conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
    View official trial listing →
  • Completed NCT NCT06439602

    Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302)

    Not yet reported Arthrosi Therapeutics 818 participants Est. completion 2026-04-10 68 sites Stand-alone
    Other conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
    View official trial listing →
  • Active, not recruiting NCT NCT06603142

    Phase II/III Study of AR882 Capsules Compared to Febuxostat Tablets in Patients with Primary Gout and Hyperuricemia

    Not yet reported, Not yet reported Guangzhou Ruianbo Pharmaceutical Technology Co., Ltd 636 participants Est. completion 2026-04 1 site Stand-alone
    Other conditions: Primary Gout, Hyperuricemia
    View official trial listing →
  • Completed NCT NCT06846515

    Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)

    Not yet reported Arthrosi Therapeutics 866 participants Est. completion 2026-09-18 83 sites Stand-alone
    Other conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic
    View official trial listing →
  • Active, not recruiting NCT NCT07116746

    Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients

    Not yet reported Arthrosi Therapeutics 15 participants Est. completion 2027-02 8 sites Stand-alone
    Other conditions: Gout, Gouty Arthritis, Hyperuricemia, Gout Chronic, Refractory Gout, Uncontrolled Gout, Tophaceous Gout
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: AR882, AR882 50 mg, AR882 75 mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.